Protalix Biotherapeutics(PLX)

Focus: Protalix is a public biotechnology company specializing in plant-derived recombinant therapeutics, operating as a mid-cap biotech with $65M in FY2025 revenue. The company leverages proprietary plant-based manufacturing technology to develop therapeutic proteins.

Profile data last refreshed 19h ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About Protalix Biotherapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow Protalix Biotherapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

0 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Revenue

$65M

FY2025

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Founded: 2024

SEC Filings: 2 available

Help build intelligence for Protalix Biotherapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Public company status provides equity liquidity and institutional stability rarely found in early-stage biotech
Differentiated platform technology (plant-derived recombinants) offers technical depth and IP moat vs. competitors
26% R&D intensity shows meaningful investment in pipeline advancement despite modest revenue base

Watch Out For

Only 1 active job posting suggests minimal hiring momentum and limited internal mobility
Swung from $14.9M net loss (FY2024) to $8M net income (FY2025)—profitability still fragile with only $20M cash
Zero active clinical trials and empty pipeline data indicate stalled development or licensing challenges

Generated by Claude from Protalix Biotherapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Financials (FY2025)

Revenue

$65M37%

R&D Spend

$17M(26%)42%

Net Income

$8M

Cash

$20M

Source: SEC 10-K Filing

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo